Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery
NCT03841058
Recruiting
This is a prospective randomized, double-blinded, placebo-controlled, phase 2, 12-month pilot to study the efficacy of abaloparatide in postmenopausal women needing lumbar spinal fusion surgery. A total of 72 women with low bone mass who are scheduled to undergo spinal fusion surgery will be randomized 2:1 in a blinded fashion to receive either 80 mcg of abaloparatide subcutaneously (SC) every day or an identical-appearing placebo SC for 6 months. As well as a total of 24 men in an open-label de... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
07/22/2025
Locations: Hospital for Special Surgery, New York, New York
Conditions: Spinal Fusion
Register for Updates
Prophylactic Reinforcement of Ventral Abdominal Incisions Trial
NCT03911700
Recruiting
This trial is being conducted to evaluate the efficacy of Phasix™ Mesh implantation at the time of midline fascial closure compared to primary suture closure in preventing a subsequent incisional hernia in subjects at risk for incisional hernia after open midline laparotomy surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: Dignity Health, Phoenix, Arizona +41 locations
Conditions: Open Midline Laparotomy
Register for Updates
Pragmatic Pediatric Trial of Balanced Versus Normal Saline Fluid in Sepsis
NCT04102371
Recruiting
The objectives of this multicenter pragmatic clinical trial are to compare the effectiveness and relative safety of balanced fluid resuscitation versus 0.9% "normal" saline in children with septic shock, including whether balanced fluid resuscitation can reduce progression of kidney injury.
Gender:
ALL
Ages:
Between 2 months and 17 years
Trial Updated:
07/22/2025
Locations: UC Davis: University of California, Davis, Davis, California +23 locations
Conditions: Shock, Septic
Register for Updates
Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
NCT04262466
Recruiting
Brenetafusp (IMC-F106C) is an immune-mobilizing monoclonal T cell receptor against cancer (ImmTAC ®) designed for the treatment of cancers positive for the tumor-associated antigen PRAME. This is a first-in-human trial designed to evaluate the safety and efficacy of brenetafusp in adult participants who have the appropriate HLA-A2 tissue marker and whose cancer is positive for PRAME.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: University of California - San Diego, La Jolla, California +75 locations
Conditions: Select Advanced Solid Tumors
Register for Updates
Autonomic Regulation of Blood Pressure in Premature and Early Menopausal Women
NCT04439370
Recruiting
This is a cross-sectional study in which the investigators will determine the impact of premature/early menopause on MSNA, BP and baroreflex sensitivity in younger (≤49 yr old) and older (≥50 yr old) women. Specifically, aim one will determine mechanisms driving autonomic dysregulation of BP in premature and early menopausal women and aim two will determine mechanisms driving autonomic dysregulation of BP in older menopausal women. The study design outlined below will permit testing of aim one a... Read More
Gender:
FEMALE
Ages:
Between 35 years and 70 years
Trial Updated:
07/22/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Hypertension, Menopause, Premature, Menopause, Blood Pressure
Register for Updates
A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine
NCT04616326
Recruiting
The main purpose of this study is to evaluate the efficacy and safety of galcanezumab for the preventive treatment of chronic migraine in participants 12 to 17 years of age. The primary objective is to demonstrate the superiority of galcanezumab versus placebo in the reduction of monthly migraine headache days across the 3-month double-blind treatment period.
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
07/22/2025
Locations: Rehabilitation & Neurological Services, Huntsville, Alabama +88 locations
Conditions: Chronic Migraine
Register for Updates
Staged Complete Revascularization for Coronary Artery Disease vs Medical Management Alone in Patients With AS Undergoing Transcatheter Aortic Valve Replacement
NCT04634240
Recruiting
Patients undergoing transcatheter aortic valve replacement (TAVR) often have concomitant coronary artery disease (CAD) which may adversely affect prognosis. There is uncertainty about the benefits and the optimal timing of revascularization for such patients. There is currently clinical equipoise regarding the management of concomitant CAD in patients undergoing TAVR. Some centers perform routine revascularization with percutaneous coronary intervention (PCI) (either before or after TAVR), while... Read More
Gender:
ALL
Ages:
All
Trial Updated:
07/22/2025
Locations: Huntsville Heart Center, Huntsville, Alabama +71 locations
Conditions: Aortic Stenosis, Coronary Artery Disease, Coronary Stenosis
Register for Updates
Oral Pyridoxal 5'-Phosphate for the Treatment of Patients With PNPO Deficiency
NCT04706013
Recruiting
The proposed clinical study is intended to evaluate oral P5P for the treatment of patients confirmed to have Pyridox(am)ine 5'-Phosphate Oxidase (PNPO) deficiency via genetic analysis. There is an unmet clinical need for pharmaceutical grade P5P, as to date none has been made commercially available. Patients will receive pharmaceutical grade P5P according to their normal oral P5P dosing regimen, as previously established by their physicians.
Gender:
ALL
Ages:
All
Trial Updated:
07/22/2025
Locations: Children's Hospital of Alabama, Birmingham, Alabama +5 locations
Conditions: Pyridox(am)Ine 5'-Phosphate Oxidase Deficiency
Register for Updates
Parenteral Ascorbic Acid Repletion in TransplantatIon
NCT04756063
Recruiting
A single-center, randomized, double-blinded placebo-controlled trial is proposed to investigate administration of supraphysiologic doses of ascorbic acid (vitamin C, AA) to patients undergoing liver transplantation. Participants randomized to the intervention group will receive intravenous (IV) AA 1500 mg every 6 hours for 48 hours. Participants randomized to the control group will receive a saline placebo. The primary study outcome will be a change in the Sequential Organ Failure Assessment (SO... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
07/22/2025
Locations: University of Wisconsin Hospital and Clinics, Madison, Wisconsin
Conditions: Liver Transplant Failure and Rejection
Register for Updates
Neural Correlates of Real World Spatial Navigation in Humans
NCT04874220
Recruiting
The purpose of this study is to understand the neural mechanisms that support real world spatial navigation in humans using deep brain recordings and stimulation during virtual reality (VR), augmented reality, and real world memory tasks. We will determine the cognitive (i.e., memory) and behavioral (i.e., body, head, eye position and movement) factors that modulate deep brain activity and the consequent effects of memory-enhancing deep brain stimulation.
Gender:
ALL
Ages:
Between 12 years and 70 years
Trial Updated:
07/22/2025
Locations: University of California Los Angeles, Los Angeles, California
Conditions: Memory, Delayed
Register for Updates
Ceribell Delirium Data Collection Study
NCT04962815
Recruiting
This study is designed as a prospective, non-randomized, observational clinical study. The study will collect clinical and rrEEG (Ceribell EEG) data when monitoring subjects for delirium subtypes. EEG and clinical data will be collected for the development of future software algorithms to assess the presence and severity of delirium.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2025
Locations: Stanford University, Stanford, California +6 locations
Conditions: Delirium
Register for Updates
Opioid Antagonism in Hypogonadotropic Hypogonadism
NCT04975334
Recruiting
The goal of this study is to evaluate the effects of opioid antagonists on the hypothalamic-pituitary-gonadal axis in subjects with hypogonadotropic hypogonadism (HH).
Gender:
MALE
Ages:
Between 18 years and 75 years
Trial Updated:
07/22/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Hypogonadotropic Hypogonadism, Low Testosterone
Register for Updates